105 results
DEFM14A
FUSN
Fusion Pharmaceuticals Inc
25 Apr 24
Proxy related to merger
4:13pm
of such Shares to exercise such right to dissent on the Shareholder’s behalf. It is strongly suggested that any Shareholder wishing to dissent seek independent … of independent directors to (1) manage day-to-day matters related to the transaction process in order to provide an efficient manner in which to actively
PREM14A
FUSN
Fusion Pharmaceuticals Inc
10 Apr 24
Preliminary proxy related to merger
4:42pm
on the Shareholder’s behalf. It is strongly suggested that any Shareholder wishing to dissent seek independent legal advice, as the failure to comply strictly … Committee of independent directors to (1) manage day-to-day matters related to the transaction process in order to provide an efficient manner
8-K
FUSN
Fusion Pharmaceuticals Inc
9 Apr 24
Other Events
4:10pm
-2265 demonstrated meaningful improvement in secondary endpoints which include maximum % PSA decline, and independent reviewer-assessed response rates
S-8
crlslp8whcjbjgn9r
20 Mar 24
Registration of securities for employees
4:30pm
S-8
EX-23.1
0p9wnnl1whw1pvh
20 Mar 24
Registration of securities for employees
4:30pm
S-8
EX-5.1
5e9 d693cusyysxssxdl
20 Mar 24
Registration of securities for employees
4:30pm
DEFA14A
eaollaf5e
19 Mar 24
Additional proxy soliciting materials
6:25am
8-K
EX-2.1
zeeed2
19 Mar 24
Voting and Support Agreement
6:24am
8-K
EX-10.1
fcfatku1tg3qjjt3tzl
16 Feb 24
Entry into a Material Definitive Agreement
4:05pm
8-K
EX-5.1
qubrqsme
19 Jan 24
Entry into a Material Definitive Agreement
4:13pm
424B5
qkopf
19 Jan 24
Prospectus supplement for primary offering
4:10pm
8-K
EX-99.2
q1c yf25e
4 Jan 24
Fusion Pharmaceuticals Announces Clinical Program and Manufacturing Updates
4:31pm
8-K
k5k1nqw2jhe8w1oy
16 Oct 23
Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors
4:30pm